STEMLINE THERAPEUTICS INC
NASDAQ
US Flag
STML

STML
STEMLINE THERAPEUTICS INC
US Flag
NASDAQ
 
Next Earning
Market Cap
EPS
Div Yield
P/E
Next Earning
Market Cap
EPS
Div Yield
P/E

STML Stock Chart

Financials

Valuation
Enterprise Value/EBITDA, TTM
Enterprise Value, FQ
Market Cap — Basic
Number of Employees
Number of Shareholders
Price/Earnings, TTM
Price/Revenue, TTM
Price/Book Ratio, FY
Price/Sales Ratio, FY
Balance Sheet
Current Ratio, FQ
Debt to Equity, FQ
Net Debt, FQ
Quick Ratio, FQ
Total Assets, FQ
Total Debt, FQ
Operating Metrics
Return on Assets, TTM
Return on Equity, TTM
Return on Invested Capital, TTM
Revenue per Employee, TTM
Price History
Average Volume (10 day)
Beta - 1 Year
Price - 52 Week High
Price - 52 Week Low
Dividends
Dividends Paid, FY
Dividends per Share, FY
Expected Annual Dividends
Dividends Yield
Margins
Net Margin, TTM
Gross Margin, TTM
Operating Margin, TTM
Pretax Margin, TTM
Income Statement
Basic EPS, Net Income
Earnings per Share, Basic, TTM
EBITDA, TTM
Gross Profit, FY
Last Annual EPS
Last Annual Revenue, FY
Net Income, FY
Total Revenue, FY
Free Cash Flow, TTM

Profile

Sector: Healthcare
Industry: Biotechnology & Medical Research
Employees: 96
Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers. SL-401 consists of IL-3 recombinantly fused to a truncated diphtheria toxin payload. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. SL-701 comprises various short synthetic peptides that correspond to epitopes of targets, including IL-13 receptor subunit alpha-2 (IL-13Ra2), ephrin type-A receptor 2 (EphA2) and survivin, present on brain cancer. SL-801 is an oral, small molecule that reversibly inhibits Exportin-1 (XPO1), also known as Chromosome Region Maintenance-1 (CRM-1), a nuclear transport protein.

News

Home Stock Screener Forex Screener Crypto Screener Economic Calendar How It Works Chart Features Pricing House Rules Moderators Website & Broker Solutions Widgets Charting Solutions Help Center Feature Request Blog & News FAQ Wiki Twitter
Profile Profile Settings Account and Billing TradingView Coins My Support Tickets Help Center Ideas Published Followers Following Private Messages Chat Sign Out